ClinicalTrials.gg
CompletedNCT00078338Updated Jun 27, 2018Results posted

Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis

A Phase 4 interventional study of Rebif® and Copaxone® in Relapsing-remitting Multiple Sclerosis, sponsored by EMD Serono. Completed at 80 sites in 12 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2018-06-27.

Sponsored by EMD Serono (part of Merck KGaA, Darmstadt, Germany) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
764
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing Interferon beta-1a in Multiple Sclerosis, Relapsing-Remitting — none open to participants now, none under way, none of them phase 3. Interferon beta-1a · Multiple Sclerosis, Relapsing-Remitting.

Enrollment
2nd of 21
764 · median 80
Started
2004
with 3 others
Phase 4
13 of 21
none open now
Registered
1st of 21
by date
Lead sponsor
3 of 21
EMD Serono

Among the 21 studies testing Interferon beta-1a in Multiple Sclerosis, Relapsing-Remitting, this one is the 2nd largest by enrollment, is one of 4 that started in 2004, is one of 13 in phase 4, and was the 1st registered.

Multiple Sclerosis, Relapsing-Remitting

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Open to participants now

None of the 21 studies testing Interferon beta-1a in Multiple Sclerosis, Relapsing-Remitting is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →

About Interferon beta-1a

Interferon beta-1a: first FDA approval 1996 (AVONEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 21 studies testing Interferon beta-1a in Multiple Sclerosis, Relapsing-Remitting as a file.
02

Study summary

The primary objective of the study is to assess the clinical efficacy of Rebif® 44 microgram (mcg) three times per week compared with Copaxone® 20 milligram (mg) daily in subjects with relapsing Multiple Sclerosis.

03

Conditions studied

  • Relapsing-remitting Multiple Sclerosis
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be between 18 and 60 years of age
  • Have definite relapsing multiple sclerosis
  • Have had one or more relapses within the prior 12 months
  • Must be in a clinically stable or improving neurological state during the four weeks prior to Study Day 1
  • Expanded Disability Status Scale (EDSS) score from 0 to 5.5, inclusive
  • If female, she must either be or surgically sterilized; or use a hormonal , intra uterine device, diaphragm with spermicide, or condom with spermicide, for the duration of the study; and be neither pregnant nor breast-feeding
  • Confirmation that the subject is not pregnant must be established by a negative serum human chorionic gonadotropin (hCG) pregnancy test within 7 days of Study Day 1 and a negative urine pregnancy test on Study Day 1. A pregnancy test is not required if the subject is post-menopausal or surgically sterilized
  • Be willing and able to comply with the protocol for the duration of the study
  • Voluntarily provide written and, for USA sites only, a subject authorization under Health Insurance Portability and Accountability Act (HIPAA), prior to any study-related procedure that is not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to their future medical care

Exclusion criteria

Exclusion Criteria:

  • Have secondary progressive multiple sclerosis (SPMS) or primary progressive MS (PPMS)
  • Prior use of any interferon or glatiramer acetate
  • Have had treatment with oral or systemic or adrenocorticotrophic hormone (ACTH) within 4 weeks of Study Day 1 and within 7 days prior to the Day 1 magnetic resonance imaging (MRI)
  • Have a psychiatric disorder that is unstable or would preclude safe participation in the study.
  • Have significant leukopenia (white blood cell count \< 0.5 times the lower limit of normal of the central laboratory) within 7 days of Study Day 1.
  • Have elevated liver function tests ( [AST], aspartate aminotransferase [ALT], alkaline phosphatase > 2.0 times the [ULN] of the central laboratory, or total > 1.5 times the ULN of the central laboratory) within 7 days of Study Day 1 or a history of hepatitis (including infectious or drug-induced)
  • Prior cytokine or anti-cytokine therapy within 3 months prior to Study Day 1
  • Prior use of immunomodulatory or therapy (including but not limited to cyclophosphamide, cyclosporin, methotrexate, azathioprine, linomide, mitoxantrone) within the 12 months prior to Study Day 1
  • Prior use of cladribine or have received total lymphoid irradiation
  • Have allergy or to human serum albumin, mannitol, glatiramer acetate, natural or recombinant interferon-β, or any other components of the study drugs or gadolinium diethylenetriaminepentaacetic acid
  • Have taken intravenous immunoglobulin or any other drug or taken part in any experimental procedure in the 6 months prior to Study Day 1.
  • Presence of systemic disease that might interfere with subject safety, compliance or evaluation of the condition under study (e.g. insulin-dependent diabetes, Lyme disease, cardiac disease, [HIV], human T-cell lymphotrophic virus type I [HTLV-1])
  • Have had plasma exchange in 3 months prior to Study Day 1.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
764 participants (actual)

Study arms

  • Experimental
    Rebif®

    Drug: Rebif®

  • Active comparator
    Copaxone®

    Drug: Copaxone®

Interventions

  • Subjects will be administered with Rebif® (Recombinant interferon beta-1a) as subcutaneous (SC) injection at a dose of 44 microgram (mcg) three times weekly (tiw).

    Also known as: Recombinant interferon beta-1a

  • Subjects will be administered with Copaxone® (Glatiramer acetate) as subcutaneous (SC) injection at a dose of 20 milligram (mg) once daily (qd).

    Also known as: Glatiramer acetate

06

What researchers measure

Primary outcomes

  1. Time to First Relapse

    Relapse was defined as new, worsening or recurrent neurological symptoms attributed to multiple sclerosis that last for at least 24 hours without fever or infection, or adverse reaction to prescribed medication, preceded by a stable or improving neurological status of at least 30 days. These new or worsening symptoms should be noted by subject and must be accompanied by at least 1 of the following: An increase of greater than or equal to (\>=) 1 grade in \>=2 functional scales of the Expanded Disability Status Scale (EDSS) or an increase of \>=2 grades in 1 functional scale of the EDSS or an increase of \>= 0.5 or an increase of \>=1.0 in EDSS if the previous EDSS was 0. Time to first relapse was defined as the time in days from the date of first dose of study treatment to the date of first multiple sclerosis relapse. The mean time to first relapse for the 25th percentile and the 30th percentile during the 96-week treatment period was measured by Kaplan-Meier estimates and was reported.

    Time frame: Baseline up to 96 weeks

07

Results

Posted Jun 27, 2018

Participant flow

Participant flow — Overall Study
MilestoneRebif®Copaxone®
Started386378
Safety population381375
Completed301324
Not completed8554
Withdrew: Adverse event3124
Withdrew: Lost to follow-up172
Withdrew: Protocol violation22
Withdrew: Disease progression47
Withdrew: Other2816
Withdrew: Subjects randomized, but not treated33

Outcome measures

PrimaryTime to First Relapse

Relapse was defined as new, worsening or recurrent neurological symptoms attributed to multiple sclerosis that last for at least 24 hours without fever or infection, or adverse reaction to prescribed medication, preceded by a stable or improving neurological status of at least 30 days. These new or worsening symptoms should be noted by subject and must be accompanied by at least 1 of the following: An increase of greater than or equal to (\>=) 1 grade in \>=2 functional scales of the Expanded Disability Status Scale (EDSS) or an increase of \>=2 grades in 1 functional scale of the EDSS or an increase of \>= 0.5 or an increase of \>=1.0 in EDSS if the previous EDSS was 0. Time to first relapse was defined as the time in days from the date of first dose of study treatment to the date of first multiple sclerosis relapse. The mean time to first relapse for the 25th percentile and the 30th percentile during the 96-week treatment period was measured by Kaplan-Meier estimates and was reported.

Time frame:
Baseline up to 96 weeks
Reported as:
Mean · days
Time to First Relapse
daysRebif®Copaxone®
25th Percentile332.0 ± 10.9290.0 ± 9.5
30th Percentile495.0 ± 16.3432.0 ± 14.2
Statistical analysis
  • Rebif® vs Copaxone® · Cox proportional hazards model · p = 0.643 · Hazard ratio (hr): 0.943 · 95% CI 0.74 to 1.21

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rebif®—29/381 (7.6%)346/381 (90.8%)
Copaxone®—27/375 (7.2%)320/375 (85.3%)
Most frequent serious events
Showing 10 of 64
Most frequent serious events
EventRebif®Copaxone®
IleusGastrointestinal disorders0/3812/375
Face oedemaGeneral disorders0/3812/375
LaryngospasmRespiratory, thoracic and mediastinal disorders0/3812/375
Chest painGeneral disorders2/3811/375
DepressionPsychiatric disorders2/3811/375
Acute sinusitisInfections and infestations1/3811/375
Upper respiratory tract infectionInfections and infestations1/3811/375
Urinary tract infectionInfections and infestations1/3811/375
Chronic sinusitisInfections and infestations0/3811/375
DiverticulitisInfections and infestations0/3811/375
Most frequent other events
Showing 10 of 23
Most frequent other events
EventRebif®Copaxone®
Injection site erythemaGeneral disorders121/381114/375
Influenza like illnessGeneral disorders119/3815/375
Injection site pruritusGeneral disorders8/38175/375
HeadacheNervous system disorders74/38135/375
Injection site painGeneral disorders47/38153/375
NasopharyngitisInfections and infestations34/38144/375
Injection site swellingGeneral disorders4/38142/375
Injection site bruisingGeneral disorders33/38138/375
DepressionPsychiatric disorders30/38122/375
SinusitisInfections and infestations18/38129/375

Baseline characteristics

The intent to treat (ITT) population consisted of all subjects who were randomized.

Age, Customized
Age, Customized(Participants)Rebif®Copaxone®Total
Less than 18 years000
18 years to 64 years386378764
Greater than 64 years000
Sex: Female, Male
Sex: Female, Male(Participants)Rebif®Copaxone®Total
Female267272539
Male119106225
08

Study locations

80 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35249, United States
  • Barrow Neurology Clinics
    Phoenix, Arizona 85013, United States
  • Northwest NeuroSpecialists
    Tucson, Arizona 85741, United States
  • University of California, Davis
    Sacramento, California 95817, United States
  • Kaiser Permanente Neurology
    San Diego, California 92102, United States
  • Advanced Neurology of Colorado, LLC
    Fort Collins, Colorado 80528, United States
  • The MS Treatment Center at Griffin Hospital
    Derby, Connecticut 06418, United States
  • Associated Neurologists of Southern Connecticut, P.C.
    Fairfield, Connecticut 06824, United States
  • Neurological Center of South Florida
    Miami, Florida 33176, United States
  • Harbourside Medical Plaza
    Tampa, Florida 33606, United States
  • Shepherd Center
    Atlanta, Georgia 30309, United States
  • University Chicago Hospitals
    Chicago, Illinois 60619, United States
  • Consultants In Neurology, Ltd.
    Northbrook, Illinois 60062, United States
  • Fort Wayne Neurological Center
    Fort Wayne, Indiana 46805, United States
  • University of Maryland MD Center for MS
    Baltimore, Maryland 21201, United States
  • University Of Michigan
    Ann Arbor, Michigan 48109, United States
  • Wayne State University
    Detroit, Michigan 48201, United States
  • Henry Ford Hospital Dept of Neurology
    Detroit, Michigan 48202, United States
  • The Minneapolis Clinic of Neurology
    Golden Valley, Minnesota 55422, United States
  • University of Minnesota Medical School, Dept of Neurology
    Minneapolis, Minnesota 55455, United States
  • Nevada Neurological Consultants
    Henderson, Nevada 89052, United States
  • Albany Medical College Dept of Neurology MC-70
    Albany, New York 12208, United States
  • Neurology University of Rochester
    Rochester, New York 14642, United States
  • SUNY At Stony Brook U Hospital - Department of Neurology
    Stony Brook, New York 11794, United States
  • SUNY Upstate Medical University Dept of Neurology
    Syracuse, New York 13210, United States
  • MS Center/CHS
    Charlotte, North Carolina 28207, United States
  • Wake Forest Univ. Health Sciences
    Winston-Salem, North Carolina 27157, United States
  • Ohio State University
    Columbus, Ohio 43210, United States
  • Oak Clinic for Multiple Sclerosis
    Uniontown, Ohio 44685, United States
  • Medford Neurological and Spine Clinic
    Medford, Oregon 97504, United States
  • University Of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Thomas Jefferson University Physicians Dept of Neurology
    Philadelphia, Pennsylvania 19107, United States
  • Baptist West Hospital
    Knoxville, Tennessee 37922, United States
  • University of Texas-Houston
    Houston, Texas 77030, United States
  • Central Texas Neurology
    Round Rock, Texas 78681, United States
  • Neurology Health Care Service / Fletcher Allen Health Care
    Burlington, Vermont 05401, United States
  • Neurology Center of Fairfax
    Fairfax, Virginia 22031, United States
  • Blue Ridge Research Center
    Roanoke, Virginia 24014, United States
  • Minor & James Medical, PLLC
    Seattle, Washington 98104, United States
  • CAMC Institute
    Charleston, West Virginia 25304, United States
  • Center for Neurological Disorders
    Milwaukee, Wisconsin 53215, United States
  • Servicio de Neurologia
    Buenos Aires, 1221, Argentina
  • Departmento Enfermedades Desmielinizantes
    Buenos Aires, 1428, Argentina
  • Servicio de Neurologia Departmento Enfermedades Desmielinizantes
    Buenos Aires, C118ACH, Argentina
  • Seccion Neurolgia Instituto INEBA
    Buenos Aires, C1192AAW, Argentina
  • Fundacion Rosarina de Neurorehabilitacion
    Rosario, CP 2000, Argentina
  • Dept Neurologia Sanatorio Britanico de Rosario
    Rosario, Argentina
  • OO Landes-Nervenklinik
    Linz, 4020, Austria
  • Campus Ribeirao Preto Faculdade de Medicina de Sao Paolo
    Riberao Preto-SP, 14048-900, Brazil
  • Dept of Neurology CHU Timone
    Marseille, 13385, France
  • Hopital Pontchaillou
    Rennes cedex, 35033, France
  • Dept of Neurology Johannes Gutenberg University
    Mainz, 55131, Germany
  • Dept of Neurology Universitatsklinikum Munster
    Munster, 48149, Germany
  • Dept of Neurological and Psychiatric Sciences University of Bari
    Bari, 70124, Italy
  • Dept of Neurosciences Oftamology and Genetics Univ of Genoa
    Genoa, 16132, Italy
  • Dept Neurology Ospedale San Raffaele
    Milan, Italy
  • Dept of Neurological Sciences University La Sapienza Rome
    Rome, 00185, Italy
  • Academisch Ziekenhuis Vrije Universiteit
    Amsterdam, 1081, Netherlands
  • MS Center Nijmegen
    Nijmegen, 6533 PA, Netherlands
  • City Clinical Hospital No 83
    Moscow, 115682, Russian Federation
  • Dept Of Neurology and Neurosurgery, Russian State Med Univ
    Moscow, 117049, Russian Federation
  • State Instituion Central Clinical Milatary Hospital
    Moscow, 123182, Russian Federation
  • Scientific Research Center of Neurology Russian MOH
    Moscow, 125367, Russian Federation
  • Department of Neurology City Hospital #33
    Nizhniy Novgorod, 603076, Russian Federation
  • Institute of Clinical Immunology RAMS
    Novosibirsk, 630099, Russian Federation
  • Military Medical Academy
    Saint-Petersburg, 194044, Russian Federation
  • Dept of Neurology St Petersburg State Medical University
    St Petersburg, 197022, Russian Federation
  • Dept of MS Institute for Human Brain of R.A.Sci
    St Petersburg, 197376, Russian Federation
  • Dept of Neurology Medical Clinic of Russian MoH
    St Petersburg, Russian Federation
  • Chair of Nuerological Diseases and Medical Genetics
    Yaroslavl, 150030, Russian Federation
  • Neuroinmunologia Clinica Hospital Vall d'Hebron
    Barcelona, 08035, Spain
  • Servicio de Neurologia Hospital Bellvitge
    Hospitalet de Llobregat, 08907, Spain
  • Neurologia Hospital Carlos Haya
    Malaga, 29010, Spain
  • Unidad de EM Neurologia Hospital Virgen Macarena
    Sevilla, 41009, Spain
  • Dept Of Neurology
    Zurich, 8091, Switzerland
  • Department of Neurology
    Whitechapel, London E1 1BB, United Kingdom
  • Department Of Neurology Royal London Hospital
    London, E1 1BB, United Kingdom
  • Royal Victoria Infirmary
    Newcastle upon Tyne, NE1 4LP, United Kingdom
  • Div of Clinical Neurology B Floor Medical School Univ Hospital
    Nottingham, NG7 2UH, United Kingdom
  • Division of Clinical Neurology Medical School Universtity Hopsital
    Nottingham, NG7 2UH, United Kingdom
09

References and documents

Publications

  • Mikol DD, Barkhof F, Chang P, Coyle PK, Jeffery DR, Schwid SR, Stubinski B, Uitdehaag B; REGARD study group. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol. 2008 Oct;7(10):903-14. doi: 10.1016/S1474-4422(08)70200-X. Epub 2008 Sep 11. PubMed 18789766 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2004 to primary completion in Nov 2006, 33 months.

Results were first posted in Jun 2018, 11 years 6 months after primary completion.

Of 28 phase 4 interventional studies under Multiple Sclerosis, Relapsing-Remitting, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 66. This study's 33 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2004
First posted
Feb 26, 2004
StartActual
Feb 16, 2004
Primary completionActual
Nov 28, 2006
CompletionActual
Nov 28, 2006
Results first posted
Jun 27, 2018
Last update
Jun 27, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00078338
Lead sponsor
EMD Serono
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Feb 26, 2004
Start date
Feb 16, 2004
Primary completion
Nov 28, 2006
Completion
Nov 28, 2006
Results posted
Jun 27, 2018
Last update
Jun 27, 2018

Study contacts

Medical Responsible
study director · Merck KGaA, Darmstadt, Germany
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Interferon beta-1a

Start the discussion